News Center
-91.jpg)
All
2024
2023
2022
2021
2020
-
LaNova Medicines Announces IND Approval of LM-24C5 by US FDA2023-09-28
Learn More
-
-91.jpg)
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate12 May, 2023, LaNova Medicines announced today it has entered into an exclusive license agreement with AstraZeneca for anti-GPRC5D ADC LM-305
2023-05-12Learn More
-
LaNova Medicines and LegoChem evaluate novel first-in-class antibody drug conjugate candidate2023-04-26
Learn More
-
LM-108 Receives Fast Track Designations for Cancer Treatments from US FDA2023-04-21
Learn More
-
LaNova Medicines Announces the IND Approval of LM-101 by NMPAShanghai November 15th, 2022 – LaNova Medicines Ltd. announced that the investigational new drug (IND) of LM-101, an anti-SIRPα monoclonal antibody, has been approved by China NMPA.
2022-11-15Learn More
-
LaNova Medicines Announces the IND Approval of LM-305, a GPRC5D-targeting ADC Drug by NMPA
Shanghai November 10th, 2022 – LaNova Medicines Ltd. announces that the investigational new drug (IND) of LM-305, an ADC drug targeting GPRC5D, has been approved by China NMPA.
2022-11-10Learn More